Recent studies have uncovered increasing evidence showing that in addition to its role as an escape mechanism of anti‐VEGF therapies, deregulated FGFRs can function as driving oncogenes in certain tumor types, acting in a cell‐autonomous fashion to maintain the malignant properties of cancer cells (Knights and Cook, 2010; Korc and Friesel, 2009; Roidl et al., 2009). The gene discussed is VEGFA; the disease is cancer.